XenoPort sinks on Phase II psoriasis data

XenoPort Inc. (NASDAQ:XNPT) fell $1.89 (28%) to $4.84 after reporting data from a Phase II trial of XP23289 to treat moderate to severe chronic plaque-type psoriasis. Two doses of XP23829 met the primary endpoint, but the results were eclipsed by adverse events (AEs) in the trial.

The twice-daily 400 mg and once-daily 800 mg doses of XP23829 showed significant improvements at week 12 in percent change from baseline in Psoriasis Area and Severity Index (PASI) score (p<0.001 and p=0.001, respectively). The once-daily 400 mg dose did not meet the primary endpoint. ...